Replimune Group, Inc. (NASDAQ:REPL) Receives Average Recommendation of "Hold" from Analysts

Key Points

• Replimune Group, Inc. has received a consensus recommendation of "Hold" from ten analysts, with an average target price of $6.50.
• Recent downgrades from various analysts, including BMO Capital Markets and HC Wainwright, have significantly lowered their target prices for the stock.
• Insider trading activity includes CFO Emily Luisa Hill selling over 9,000 shares of the company's stock, indicating a 6.38% decrease in her holdings.

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) has received a consensus recommendation of "Hold" from the ten analysts that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, seven have given a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $6.50.

Several equities analysts recently commented on the company. BMO Capital Markets downgraded Replimune Group from an "outperform" rating to an "underperform" rating and cut their target price for the stock from $27.00 to $2.00 in a research report on Wednesday, July 23rd. Cantor Fitzgerald upgraded Replimune Group from a "neutral" rating to an "overweight" rating in a research report on Wednesday, July 30th. HC Wainwright downgraded Replimune Group from a "buy" rating to a "neutral" rating in a research report on Wednesday, July 23rd. Piper Sandler downgraded Replimune Group from an "overweight" rating to a "neutral" rating and set a $3.00 target price for the company. in a research report on Tuesday, July 22nd. Finally, JPMorgan Chase & Co. restated a "neutral" rating and set a $9.00 target price (down previously from $19.00) on shares of Replimune Group in a research report on Tuesday, July 22nd.

Insiders Place Their Bets

In related news, CFO Emily Luisa Hill sold 9,154 shares of the firm's stock in a transaction on Friday, August 15th. The stock was sold at an average price of $5.37, for a total transaction of $49,156.98. Following the completion of the sale, the chief financial officer directly owned 134,368 shares of the company's stock, valued at $721,556.16. This trade represents a 6.38% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 5.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Replimune Group

Hedge funds and other institutional investors have recently bought and sold shares of the business. US Bancorp DE increased its holdings in Replimune Group by 582.6% during the 1st quarter. US Bancorp DE now owns 4,594 shares of the company's stock valued at $45,000 after purchasing an additional 3,921 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in Replimune Group by 37.5% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company's stock valued at $64,000 after purchasing an additional 1,879 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in Replimune Group during the 2nd quarter valued at $69,000. Tower Research Capital LLC TRC increased its holdings in Replimune Group by 696.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,772 shares of the company's stock valued at $82,000 after purchasing an additional 5,922 shares in the last quarter. Finally, Tower Research Capital LLC TRC increased its holdings in Replimune Group by 2,020.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 9,692 shares of the company's stock valued at $90,000 after purchasing an additional 9,235 shares in the last quarter. 92.53% of the stock is owned by institutional investors and hedge funds.

Replimune Group Price Performance

Shares of REPL stock opened at $6.33 on Monday. The company has a current ratio of 6.94, a quick ratio of 6.94 and a debt-to-equity ratio of 0.21. The company has a market capitalization of $494.12 million, a P/E ratio of -1.95 and a beta of 0.51. Replimune Group has a 12 month low of $2.68 and a 12 month high of $17.00. The stock has a 50 day moving average of $7.02 and a two-hundred day moving average of $8.68.

Replimune Group (NASDAQ:REPL - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.12). As a group, equities analysts expect that Replimune Group will post -2.97 EPS for the current year.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.